All In Biotech

Drug Trial Radar · NCT07395232

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Participants With Atopic Keratoconjunctivitis (AKC)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Mar 2027

Study completion May 2027

Sponsor

Lead sponsor
Dompé Farmaceutici S.p.AIndustry
Sponsor type
Industry
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.

Conditions

  • Atopic Keratoconjunctivitis

Interventions

  • DFL24498Drug

    DFL24498 will be instilled in each eye for 12 Weeks.

  • VehicleDrug

    Vehicle eye drops without active drug will be instilled in each eye for 12 Weeks.

  • dexamethasone sodium phosphate (DSP) ophthalmic solutionDrug

    Rescue medication may be administered as required at the Investigator discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS).Time frame: Baseline and at Week 6

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • Bowden Eye Associates - Southside Location

    Jacksonville, Florida · Recruiting

  • University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute

    Miami, Florida · Recruiting

  • Clayton Eye Clinical Research

    Morrow, Georgia · Recruiting

  • Ophthalmology Associates

    St Louis, Missouri · Recruiting

  • NYU Langone Health - Eye Center

    New York, New York · Recruiting

  • Duke Eye Center - Ophthalmology

    Durham, North Carolina · Recruiting

  • Total Eye Care, PA

    Memphis, Tennessee · Recruiting

  • Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology

    Houston, Texas · Recruiting

  • IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia

    Bologna, Italy · Recruiting

  • Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti

    Chieti, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy · Recruiting

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Roma, Italy · Recruiting

  • AOU Policlinico Umberto I

    Roma, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy · Recruiting

  • METAVISION ARRUZAFA S.L. (Hospital Arruzafa)

    Córdoba, Spain · Recruiting

  • Miranza Galicia

    Santiago de Compostela, Spain · Recruiting

  • Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM)

    Valencia, Spain · Recruiting

  • OBA - Universidad de Valladolid

    Valladolid, Spain · Recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.